All In Biotech

Drug Trial Radar · NCT02925234

The Drug Rediscovery Protocol (DRUP Trial)

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,550

Planned (sponsor's estimate)

Start

Aug 2016

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Lead sponsor
The Netherlands Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Novartis; Roche Pharma AG; Merck Sharp & Dohme LLC; Boehringer Ingelheim; Ipsen; Eisai Inc.; Pfizer; Clovis Oncology - Pharma and; Eli Lilly and Company; Janssen, LP; GlaxoSmithKline; Incyte Corporation; Dutch Cancer Society; Stelvio for Life
First posted
Oct 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must have been performed on the tumor and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Results from the molecular profiling test will be used to determine an appropriate drug(s) from among those available in the protocol. The choice of drug will be supported by a list of potential profiles, a molecular tumor board, a knowledge library and by study coordinators for review and approval of the match. The protocol-specified treatment will be administered to the patient once any drug-specific eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future genetic studies. All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment. In addition, treatment related toxicity will be evaluated.

Conditions

  • Cancer
  • Tumors
  • Neoplasm
  • Neoplasia

Interventions

  • PanitumumabDrug

    Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.

  • OlaparibDrug

    Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.

  • DabrafenibDrug

    Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.

  • NilotinibDrug

    Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.

  • TrametinibDrug

    Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.

  • ErlotinibDrug

    Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.

  • Trastuzumab and Pertuzumab (combination treatment)Drug

    Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.

  • Vemurafenib and Cobimetinib (combination treatment)Drug

    Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.

  • VismodegibDrug

    Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.

  • RegorafenibDrug

    Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.

  • NivolumabDrug

    Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.

  • AfatinibDrug

    Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.

  • Dabrafenib and trametinibDrug

    Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.

  • RibociclibDrug

    Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.

  • LenvatinibDrug

    Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.

  • PembrolizumabDrug

    Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.

  • DurvalumabDrug

    Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.

  • RucaparibDrug

    Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.

  • AxitinibDrug

    Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.

  • PalbociclibDrug

    Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.

  • CrizotinibDrug

    Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.

  • SunitinibDrug

    Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.

  • CabozantinibDrug

    Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.

  • AbemaciclibDrug

    Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.

  • AlectinibDrug

    Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.

  • Atezolizumab and BevacizumabDrug

    Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.

  • Ipilimumab and nivolumabDrug

    Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.

  • EntrectinibDrug

    Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.

  • TalazoparibDrug

    Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.

  • DacomitinibDrug

    Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.

  • LorlatinibDrug

    Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.

  • ErdafitinibDrug

    Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.

  • AlpelisibDrug

    Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.

  • NiraparibDrug

    Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.

  • PemigatinibDrug

    Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.

  • SelpercatinibDrug

    Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.

  • TepotinibDrug

    Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients that are treated based on their molecular tumor profileTime frame: 6 months after treatment initiation (estimated average)
  2. Objective tumor responseTime frame: 6 months after treatment initiation (estimated average)
  3. Stable diseaseTime frame: 6 months after treatment initiation (estimated average)
  4. Treatment-related grade≥3 and serious adverse eventsTime frame: 6 months after treatment initiation (estimated average)

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Noordwest ziekenhuisgroep Alkmaar (NWZ)

    Alkmaar, Netherlands · Recruiting

  • Ziekenhuisgroep Twente

    Almelo, Netherlands · Recruiting

  • Meander medisch centrum

    Amersfoort, Netherlands · Recruiting

  • Netherlands Cancer Institute

    Amsterdam, Netherlands · Recruiting

  • Amsterdam UMC, locatie VUmc

    Amsterdam, Netherlands · Recruiting

  • Amsterdam UMC, locatie AMC

    Amsterdam, Netherlands · Active not recruiting

  • Onze Lieve Vrouwe Gasthuis (OLVG)

    Amsterdam, Netherlands · Recruiting

  • Gelre ziekenhuizen

    Apeldoorn, Netherlands · Recruiting

  • Rijnstate ziekenhuis

    Arnhem, Netherlands · Recruiting

  • Amphia Ziekenhuis

    Breda, Netherlands · Recruiting

  • Reiner de Graaf Gasthuis

    Delft, Netherlands · Recruiting

  • Deventer ziekenhuis

    Deventer, Netherlands · Recruiting

  • Nij Smellinghe Ziekenhuis

    Drachten, Netherlands · Recruiting

  • Ziekenhuis Gelderse Vallei

    Ede, Netherlands · Recruiting

  • Maxima Medisch Centrum

    Eindhoven, Netherlands · Recruiting

  • Zuyderland medisch centrum

    Geleen, Netherlands · Recruiting

  • Rivas zorggroep

    Gorinchem, Netherlands · Recruiting

  • Martini ziekenhuis

    Groningen, Netherlands · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Spaarne gasthuis

    Haarlem, Netherlands · Recruiting

  • Tergooi MC

    Hilversum, Netherlands · Not yet recruiting

  • Treant zorggroep

    Hoogeveen, Netherlands · Recruiting

  • Medisch Centrum Leeuwaarden

    Leeuwarden, Netherlands · Recruiting

  • Leiden University Medical Center

    Leiden, Netherlands · Recruiting

  • Maastricht University Medical Center

    Maastricht, Netherlands · Recruiting

  • St. Antonius ziekenhuis

    Nieuwegein, Netherlands · Recruiting

  • Radboud umc

    Nijmegen, Netherlands · Recruiting

  • Bravis ziekenhuis

    Roosendaal, Netherlands · Recruiting

  • St. Fransicus Gasthuis

    Rotterdam, Netherlands · Recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Recruiting

  • Haaglanden medisch centrum

    The Hague, Netherlands · Recruiting

  • Haga ziekenhuis

    The Hague, Netherlands · Recruiting

  • Elisabeth-TweeSteden Ziekenhuis

    Tilburg, Netherlands · Recruiting

  • University Medical Center Utrecht

    Utrecht, Netherlands · Recruiting

  • VieCuri medisch centrum

    Venlo, Netherlands · Recruiting

  • Isala klinieken

    Zwolle, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.